Success Story: EB-1B Approved in 6 Days for a Biomedical Scientist Advancing Immune Regulation Research
Client’s Testimonial:
"I would like to sincerely thank you and your team for your tremendous efforts in preparing my case so thoughtfully and uniquely, and for your continuous support throughout this process.
I truly appreciate your expertise and guidance."
On May 6th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for an Assistant Research Scientist in the Field of Biomedical Sciences (Approval Notice).
General Field: Biomedical Sciences
Position at the Time of Case Filing: Assistant Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: Iowa
Approval Notice Date: May 6th, 2026
Processing Time: 6 days (Premium Processing Requested)
Case Summary:
Some biomedical discoveries matter because they clarify what happens when the immune system fails to protect the body and begins driving disease instead. This EB-1B case focused on a researcher whose work helps explain those mechanisms at both the molecular and cellular levels.
North America Immigration Law Group (Chen Immigration Law Associates) assisted with an I-140 EB-1B petition for a biomedical sciences researcher from India who was serving as an assistant research scientist. The case centered on his internationally recognized work in advanced immunology, genetics, and precision gene-editing technologies.
The client’s research record showed the kind of sustained productivity and peer recognition required for an outstanding researcher petition:
- 21 peer-reviewed journal articles and 8 abstracts
- 472 citations
- Citation record placing him among the top 1% of authors in biomedical sciences
- At least 73 completed peer reviews
- Editorial board service and guest editor service
- Research supported by the National Institute of Allergy and Infectious Diseases and the U.S. Department of Veterans Affairs
To demonstrate substantial merit and cross-disciplinary impact, the petition framed the client’s research as a dual asset for both sustainable biotechnology and advanced human therapeutics. By showcasing his success in engineering high-precision genetic tools for disease-resilient biosystems alongside his breakthroughs in mapping complex cellular pathways for targeted immunotherapies, the filing established a clear record of foundational contributions. This multi-layered narrative proved to adjudicators that his ongoing endeavors directly advance critical U.S. priorities in both bio-manufacturing innovation and public health resilience.
USCIS approved the I-140 EB-1B petition on May 6, 2026, after only 6 days of processing with Premium Processing. This rapid approval reflects the strength of a petition that clearly organized the client’s research achievements, international recognition, and continuing role in advancing biomedical science in the United States.

